Understanding the basis for acquired resistance to KRASG12C inhibitors

被引：0
|
作者：
Santos Ramos, A. [1 ]
Gomez Sanchez, D. [1 ]
Rico Lopez, S. [1 ]
Plaza Exposito, P. [1 ]
Paz-Ares, L. [2 ]
Ferrer Sanchez, I. [1 ]
机构：
[1] Inst Invest Sanitaria Hosp 12 Octubre, Madrid, Spain
[2] Hosp Univ 12 Octubre, Med Oncol Dept Edificio Maternidad, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2022.09.092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1411 / S1411
页数：1
相关论文
共 50 条
  • [21] Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Chour, Ali
    Toffart, Anne-Claire
    Berton, Elodie
    Duruisseaux, Michael
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [22] RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers
    Nichols, Robert J.
    Yang, Y. C.
    Cregg, Jim
    Schulze, Chris J.
    Wang, Zhican
    Dua, Richa
    Jiang, Jingjing
    Garrenton, Lindsay S.
    Nasholm, Nicole
    Bermingham, Alun
    Knox, John E.
    Seamon, Kyle
    Longhi, Michael
    Chou, Kang-Jye
    Li, Shaoling
    Wildes, David P.
    Singh, Mallika
    Koltun, Elena S.
    Gill, Adrian L.
    Smith, Jacqueline A. M.
    CANCER RESEARCH, 2022, 82 (12)
  • [23] KRAS Mutant Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired Resistance to KRASG12C and KRASG12D Small Molecule Inhibitors
    Desai, Neil
    Grunenberger, Audrey
    Guzman-Gonzalez, Veronica
    Cabrera, Lea
    Czuba, Elodie
    Faure, Virginie
    Josserand, Veronique
    Di Vita, Gilles
    MOLECULAR THERAPY, 2024, 32 (04) : 226 - 226
  • [24] Discovery of Quinazoline Derivatives as Potent KRASG12C Inhibitors
    Liu, Nian
    Li, Zhilong
    Liu, Rui
    Zhang, Chaoxin
    Sun, Yixiang
    Ma, Xing
    Qin, Qiaohua
    Wu, Tianxiao
    Sun, Yin
    Yin, Wenbo
    Zhang, Haoyu
    Gao, Zixuan
    Xia, Guangxin
    Zhao, Dongmei
    Cheng, Maosheng
    CHEMISTRYSELECT, 2024, 9 (39):
  • [25] TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
    Edwards, A. Cole
    Stalnecker, Clint A.
    Morales, Alexis Jean
    Taylor, Khalilah E.
    Klomp, Jennifer E.
    Klomp, Jeffrey A.
    Waters, Andrew M.
    Sudhakar, Niranjan
    Hallin, Jill
    Tang, Tracy T.
    Olson, Peter
    Post, Leonard
    Christensen, James G.
    Cox, Adrienne D.
    Der, Channing J.
    CANCER RESEARCH, 2023, 83 (24) : 4112 - 4129
  • [26] Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers
    Robichaux, Jacqulyne P.
    Galan-Cobo, Ana
    Powell, Ried T.
    Gale, Kelly A.
    He, Jun
    Zhang, Fahao
    Nilsson, Monique B.
    Zhang, Xiang
    Sobieski, Mary M.
    Nguyen, Nghi
    Clifford, Stephan C.
    Heymach, John V.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [27] Overcoming Resistance to Drugs Targeting KRASG12C Mutation
    Jiao, Delong
    Yang, Shengyu
    INNOVATION, 2020, 1 (02):
  • [28] Unlocked groove-developing covalent inhibitors of KRASG12C
    Lipford, J. Russell
    Cee, Victor
    Lanman, Brian
    Saiki, Anne
    Rex, Karen
    Volak, Laurie
    Shimanovich, Roman
    Hinkle, Beth
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 24 - 25
  • [29] The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
    Kwan, Albert K.
    Piazza, Gary A.
    Keeton, Adam B.
    Leite, Caio A.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [30] Preclinical efficacy of KRASG12C inhibitors in models of pediatric cancer
    Price, Hannah
    Stauffer, Stacey
    Powell, Katie
    Baker, Andrew
    Perciaccante, Andrew
    Hernandez, Edjay Ralph
    Odeniyide, Patience
    Pratilas, Christine
    Burgan, William
    Jenkins, Lisa
    Rossman, Kent L.
    Yohe, Marielle
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
12345